Astellas Pharma (4503) · InitiativeCited as achieved
Termination of KM Biologics' Human Vaccine Sales Agreement
First written in FY2021-Q2. 1 of 2 entries say "Achieved", first in FY2021-Q2. Latest entry: FY2021-Q3.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Business Impact from Termination or Unfavorable Amendment of Important ContractsA theme 95 companies write about · 101 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2025: 6 of 28 companies on the "Worse" side.
0 other companies' latest entry also says "Cited as achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 95 companies compared. The sentences above are computed from all 95.Full recordFilings, disclosures and news, newest first
- FY2021-Q3Cited as achievedAnnual report
「日本では、イベニティをはじめ、スーグラとスージャヌなどの新製品群の売上が引き続き増加しました。一方、シムビコート、KMバイオロジクス株式会社のヒト用ワクチン、ミカルディスファミリーの販売契約終了のほか、セレコックスの独占販売期間満了が主な売上の減少要因となりました。」
KMバイオロジクスのヒト用ワクチン販売契約終了が、日本の売上減少要因の一つとして改めて記載された。 - FY2021-Q2AchievedAnnual report
「However, revenue declined due to the expiry of the exclusive marketing periods for Vesicare, an OAB treatment in Europe, and Celecox, an anti-inflammatory and analgesic in Japan, as well as the expiration of the sales agreements for Symbicort, human vaccines of KM Biologics and the Micardis family of antihypertensive treatments.」
KMバイオロジクス株式会社のヒト用ワクチン販売契約の終了が、売上収益の減少要因の一つとして初めて記載された。契約終了時期や対象製品の詳細は本文では示されていない。